CTLA4 and hepatocellular carcinoma: Furthermore, we compared the immunotherapy efficacy of the two risk subgroups by IPS scores and found that in the anti-CTLA4 single-drug group, the anti-PD1 single-drug group, and the anti-CTLA4 and anti-PD1 combination group, the IPS scores were higher in the low-risk group (Figure 5C–5F), suggesting that patients with low-risk HCC may have greater sensitivity to immunotherapy.